AI주식인사이트AI Stock Insight
C

올리패스

244460KOSDAQ기초 의약물질 제조업

40.0 / 100

Reference Date: 2026-04-13

Financial Score10.5 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure7.0 / 15
AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

OliPass is a biotech company developing RNA therapeutics using its proprietary OPNA platform, which targets pre-mRNA to inhibit disease-causing proteins with high precision. The company is advancing pipeline programs such as OLP-1002, a non-opioid pain reliever targeting the SCN9A gene, leveraging its platform's advantages over traditional RNA therapies. Its business model includes licensing technology to pharmaceutical partners and collaborative R&D for new drug development.

Number of Employees

26people

Average Salary

51.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 33.454.0Point
PBR
7.89Industry Average 2.030.0Point

3.9x industry avg (risky)

ROE
-226.92Industry Average -4.293.5Point

52.9x industry avg (excellent)

Debt Ratio
63.41Industry Average 6.610.0Point

9.6x industry avg (risky)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼38.9% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲26.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -174.3% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position4.0Point

52w mid range (50%)

Current 1,651Won52-week high 1,65152-week low 1,651
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

12 totalPositive 0Neutral 11Negative 1
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-07
  • Neutral[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
  • Neutral[기재정정]정기주주총회결과2026-03-31
  • Neutral정기주주총회결과2026-03-30
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-30